TAS1553

· Astex Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAS1553, covering 2024-08-02 to 2024-08-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms [Phase 1]

See pricing